Calluna Pharma AS (Calluna), a clinical─stage biotechnology company pioneering first─in─class antibodies for inflammatory and fibrotic diseases, announced completion of dosing in the phase 2 AURORA study of
Summary as published by Pharma Biz.
Read the full story
The complete article is on Pharma Biz's website.
Related stories
Immunology & VaccinesLatestly
WHO Recommends Routine HPV Jabs for Girls As Young as 4
WHO vaccine advisory panel SAGE recommended Tuesday that countries consider routine HPV vaccination for girls as young as four if it improves lagging uptake, as global coverage sits at 33 percent against a 90 percent target. Experts affirmed a single-dose regimen for girls aged 9 to 14 while endorsing expanded catch-up doses to combat cervical cancer globally.
Drugs & TherapeuticsBusiness Medical Dialogues
Generate Biomedicines, Zealand Pharma Join Hands in USD 1.2 Billion AI-Driven Obesity Drug Deal
Bengaluru: Danish obesity-drug developer Zealand Pharma has partnered with US biotechnology company Generate Biomedicines to develop protein-based treatments for obesity and other metabolic diseases...
Immunology & VaccinesBusiness Medical Dialogues
BioNTech's Experimental Cancer Therapy Fails Key Trial Goal
Bengaluru: BioNTech said on Tuesday its experimental mRNA cancer immunotherapy failed to meet the first main goal of a mid-to-late-stage trial in patients with head and neck cancer.US-listed shares of...
Microbiology & Infectious DiseaseThe Hindu
Pathogens, pandemics and parleys
On infectious disease outbreaks, healthcare regulation, mental health, preventive health, and more